Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Monthly MRI reveals hidden brain bleeding patterns in elderly

NCT ID NCT06128824

Knowledge-focused Sponsor: Martin Dichgans Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study uses monthly MRI scans to closely watch brain changes in 75 people with cerebral amyloid angiopathy (CAA), a condition common in older adults that can cause bleeding and strokes. Researchers aim to understand how small bleeds and silent strokes develop over time. Participants will have monthly imaging for up to a year to track these changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict and manage bleeding and stroke risks in people with cerebral amyloid angiopathy.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2019

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will be performed in a hospital-based setting. Patients with probable CAA according to the modified Boston criteria or Boston criteria v2.0 will be further evaluated for study participation.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Probable CAA according to the modified Boston criteria with evidence of 1. cSS or fSAH 2. lobar ICH survivors without cSS or fSAH * Absence of ICH or microbleed in deep locations (basal ganglia, thalamus, brain stem) * Absence of infratentorial siderosis or infratentorial SAH * MR-/CT-/DS-angiography without evidence of cerebral aneurysm, AVM, AV-fistula or other possible etiology for the observed haemorrhagic manifestations * No history of head trauma resulting in loss of consciousness or radiologically visible traumatic brain injury * Written informed consent by patient herself/himself prior to study enrolment Exclusion Criteria: * Unwillingness to participate in high-frequency (monthly) follow-up * Severe medical condition with expected life expectancy \<1 year * Contraindications for MRI (following local guidelines of the respective study center)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebral amyloid angiopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral amyloid angiopathy Disease Progression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebral amyloid angiopathy

Contacts and locations

Locations

  • DZNE/Bonn - Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn

    Bonn, Germany

  • DZNE/Magdeburg - Universitätsklinikum Magdeburg

    Magdeburg, Germany

  • Insitute for Stroke and Dementia Research

    Munich, 81377, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.